Shopping Cart
- Remove All
- Your shopping cart is currently empty
Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 906 € | 6-8 weeks | |
50 mg | 1.178 € | 6-8 weeks | |
100 mg | 1.890 € | 6-8 weeks |
Description | Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ). |
Targets&IC50 | PPARα:1.8 μM (EC50), PPARδ:1.7 μM (EC50), PPARγ:0.08 μM (EC50) |
In vitro | Chiglitazar shows weaker PPARγ activating activity than rosiglitazone, but stronger than pioglitazone. In terms of PPARα activation, Chiglitazar shows a more potent activity than rosiglitazone, pioglitazone, or WY14643 which is a selective PPARα agonist [1]. |
In vivo | Plasma glucose levels in the MSG rats treated with Chiglitazar or rosiglitazone are significantly reduced compared with the control group treated with the vehicle, after insulin injection. Fasting PI levels are lower in animals treated with Chiglitazar and rosiglitazone than control. Chiglitazar ameliorates the HOMA indices. For IPGTT, at the 30?min after glucose loading, the glucose values in the 5 and 10?mg/kg Chiglitazar and rosiglitazone-treatment groups are significantly lower than those in the vehicle treatment group [1]. |
Molecular Weight | 572.62 |
Formula | C36H29FN2O4 |
Cas No. | 743438-45-1 |
Relative Density. | 1.25 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.